HealthCor Discloses 5.6% Stake in Affymax (AFFY)
More News related to AFFY
- Affymax to Present at UBS Global Life Sciences Conference
- Affymax (AFFY) "Significantly Undervalued"; Buy on Weakness -Baird
- Affymax (AFFY) and Takeda Agree to Suspend Clinical Development of Hematide(TM)
- Affymax to Hold Conference Call and Webcast to Provide Clinical Development Update at 5:00 P.M. Eastern Time
- Takeda and Affymax Provide Clinical Development Update for Hematide(TM) in Chemotherapy-Induced Anemia
In a 13G filing on Affymax, Inc. (Nasdaq: AFFY), HealthCor Management disclosed a 5.58% stake (845,000 shares) in the company. The firm did not show a stake in Affymax at the quarter ended 12/31/07.
Affymax, Inc. is a biopharmaceutical company developing novel drugs to improve the treatment of serious and often life-threatening conditions. Affymax's lead product candidate, Hematide(TM), is currently in Phase 3 clinical trials for the treatment of anemia associated with chronic renal failure and in a Phase 1 clinical trial for the treatment of anemia in cancer patients.
HealthCor is a New York-based hedge fund started by two former SAC Capital traders Arthur Cohen and Joseph Healey. HealthCor is one of the largest hedge funds specializing in biotech. HealthCor was founded in 2005. [LJ]
Related Categories
13GsStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
